The trial’s success bar was the FDA-agreed reduction in hypoglycemic events, and Amylyx cleared it decisively. The standing setup already included encouraging prior avexitide data and a Phase 3 readout expected in the third quarter of 2026, so a positive direction was not wholly unexpected. The filing reports a 55% reduction versus placebo in the composite of Level 2 and Level 3 events, with a rate ratio of 0.45 and p=0.000003. 〔0〕 (Primary endpoint slide)
| Measure | LUCIDITY result |
|---|---|
| Participants | 78 |
| Composite Level 2/3 event reduction vs. placebo | 55% |
| Rate ratio | 0.45 |
| 95% confidence interval | 0.32–0.63 |
| P-value | 0.000003 |
| Double-blind treatment completion | More than 90% |
The breadth of the result matters more than the headline percentage. All secondary endpoints also met statistical significance, covering Level 2 events measured by both self-monitoring blood glucose and continuous glucose monitoring, as well as Level 3 events. 〔1〕 That consistency reduces the risk that the primary result was driven by one narrow measurement approach.
Safety did not introduce an obvious offset in the topline readout. Through 16 weeks, adverse events were generally mild or moderate, and the filing reports no treatment-related serious adverse events; the most common issues were diarrhea and injection-site reactions. 〔2〕 The dataset is still small at 78 participants and topline-only, so regulatory review, durability, labeling, and commercial execution remain unresolved—but the central clinical hurdle has been cleared.
Net: this is better than merely confirming a positive setup. Prior studies had made efficacy plausible, but a statistically strong Phase 3 result across the primary and every secondary endpoint materially strengthens the case for an NDA and potential 2027 commercialization. The filing says the company expects to submit the NDA by the end of 2026, making regulatory execution the next major test. (Regulatory submission timeline) 〔3〕
Read the original 8-K on SEC EDGAR ↗